According to sources, due to concerns about falling behind competitors like Eli Lilly in India's huge potential market, the Indian team of the Danish pharmaceutical giant Novo Nordisk has been pushing for the earlier launch of its popular weight loss drug Wegovy in India to maintain its leadership position in the global weight loss drug market. Novo Nordisk had previously stated that once regulatory approvals are obtained and supply is sufficient, Wegovy may enter India in 2026. However, recently, Novo Nordisk's India team has proposed to bring forward the listing of Wegovy in India to next year, while Eli Lilly is also expected to launch its weight loss drug Mounjaro in India around the same time.
担心落后于礼来 诺和诺德印度团队敦促尽早在印推出Wegovy
The india team of Novo Nordisk is urging an early launch of Wegovy in India, fearing falling behind Eli Lilly.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.